Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, Single Arm, Single Institution Clinical Trial Of Docetaxel and Doxorubicin In Combination With Local Administration Of AD5CMV-P53 (RPR/INGN 201) In Locally Advanced Breast Cancer (LABC).

Next Previous
Search
Trial Profile

Phase II, Single Arm, Single Institution Clinical Trial Of Docetaxel and Doxorubicin In Combination With Local Administration Of AD5CMV-P53 (RPR/INGN 201) In Locally Advanced Breast Cancer (LABC).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Contusugene ladenovec (Primary) ; Docetaxel (Primary) ; Doxorubicin (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Introgen Therapeutics

Most Recent Events

  • 08 Jun 2009 New source identified and integrated (University of Texas M.D. Anderson Cancer Center).
  • 08 Jun 2009 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top